Ann Mongan, director of translational research at BMS, outlines how biomarkers hold pivotal roles in clinical trials.

Historically, pregnant women have been excluded from clinical trials due to safety concerns, but the WHO is pushing for change.

Epitopea has secured approval from the MHRA and the REC in the UK for its OVACT CTA targeting advanced high-grade serous ovarian cancer.

CatalYm has commenced dosing the first subject in its Phase II/III VINCIT trial, assessing the safety and efficacy of its lead anti-GDF-15 antibody, visugromab, in cancer-associated cachexia.

Roche has reported new findings from the Phase III METEOROID trial of Enspryng in adults and adolescents with MOGAD.

Approval for Xeltis’s aXess device was based on pivotal trial data that demonstrated 79% secondary patency and a patency-related reintervention rate of 1.3 per patient year.

At AAN 2026, Argenx announced positive results from the Phase III, double-blind, placebo-controlled, ADAPT SERON study of Vyvgart.

At AAN 2026, Cabaletta Bio announced positive results from the Phase I/II open-label, RESET-MG study of rese-cel in patients with gMG.

AstraZeneca’s tozorakimab has shown benefit in a third Phase III trial in chronic obstructive pulmonary disorder (COPD).

Agenus has reported results from a Phase II trial, evaluating the combination of BOT, BAL, and agenT-797 alongside ramucirumab and paclitaxel, in advanced PD-1 refractory gastroesophageal ...

Trump's executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.

Currently in Phase I development, TherVacB is a therapeutic vaccine candidate designed as an immune therapy for chronic hepatitis B patients.